From Stanford University's review of treatments ( https://covdb.stanford.edu/page/covid-review/ ) dated May 1: "There are also several promising investigational compounds that have not yet entered into clinical trials including single-domain Abs, ACE2 mimics, and fusion inhibitors. Several members of these drug classes are highly potent in vitro and in animal models. Although they block virus entry in a manner similar to neutralizing mAbs, they are likely to be less expensive to produce. In addition, they have the potential for intranasal and/or inhalational administration. Finally, several affordable repurposed drugs have been described that inhibit SARS-CoV-2 in vitro by plausible biochemical mechanisms but which have not yet undergone sufficient evaluation in appropriately designed clinical trials."
My question is, why not?
My question is, why not?
Because it takes a long time to design a clinical trial and once done a long time and a lot of money to actually run it. At low levels of disease it takes an eternity to get data.
Then after that, more time to analyse the data for potential effects.
Trials are happening - the UKs RECOVERY trial which amongst other things found that Dexamethasone can cut ITU deaths by 1/3 or so for example.
So things are happening but its not something that can be done quickly.
Do we know what plans are afoot to develop the treatments mentioned here?
